Cidara Therapeutics Stock Forecast, Price & News

+0.04 (+1.91 %)
(As of 09/17/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume259,833 shs
Average Volume310,294 shs
Market Capitalization$105.46 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Cidara Therapeutics logo

About Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.16 out of 5 stars

Medical Sector

374th out of 1,350 stocks

Biological Products, Except Diagnostic Industry

53rd out of 193 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

Is Cidara Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cidara Therapeutics stock.
View analyst ratings for Cidara Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Cidara Therapeutics?

Wall Street analysts have given Cidara Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cidara Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Cidara Therapeutics

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its quarterly earnings data on Thursday, August, 12th. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.40. Cidara Therapeutics had a negative net margin of 117.68% and a negative trailing twelve-month return on equity of 336.43%.
View Cidara Therapeutics' earnings history

How has Cidara Therapeutics' stock price been impacted by Coronavirus?

Cidara Therapeutics' stock was trading at $2.48 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CDTX shares have decreased by 14.1% and is now trading at $2.13.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CDTX?

2 brokerages have issued twelve-month price objectives for Cidara Therapeutics' stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Cidara Therapeutics' stock price to reach $9.50 in the next year. This suggests a possible upside of 346.0% from the stock's current price.
View analysts' price targets for Cidara Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the following people:

Who are some of Cidara Therapeutics' key competitors?

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.00%), Vanguard Group Inc. (4.11%), Alethea Capital Management LLC (2.43%), Renaissance Technologies LLC (2.17%), Millennium Management LLC (1.20%) and Geode Capital Management LLC (0.75%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian, Paul Daruwala and Timothy R Franson.
View institutional ownership trends for Cidara Therapeutics

Which major investors are selling Cidara Therapeutics stock?

CDTX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., Squarepoint Ops LLC, Charles Schwab Investment Management Inc., Bridgeway Capital Management LLC, and JPMorgan Chase & Co.. Company insiders that have sold Cidara Therapeutics company stock in the last year include Jessica Oien, Neil Abdollahian, and Paul Daruwala.
View insider buying and selling activity for Cidara Therapeutics
or view top insider-selling stocks.

Which major investors are buying Cidara Therapeutics stock?

CDTX stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Millennium Management LLC, Renaissance Technologies LLC, Tibra Equities Europe Ltd, Ergoteles LLC, Opaleye Management Inc., Parametric Portfolio Associates LLC, and XTX Topco Ltd. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine, Jeffrey Stein, and Timothy R Franson.
View insider buying and selling activity for Cidara Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $2.13.

How much money does Cidara Therapeutics make?

Cidara Therapeutics has a market capitalization of $105.46 million and generates $12.07 million in revenue each year. The biotechnology company earns $-72,110,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.

How many employees does Cidara Therapeutics have?

Cidara Therapeutics employs 79 workers across the globe.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is

Where are Cidara Therapeutics' headquarters?

Cidara Therapeutics is headquartered at 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at (858) 752-6170 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.